Translational and HIF-1α-Dependent Metabolic Reprogramming Underpin Metabolic Plasticity and Responses to Kinase...

Area of Science:

• Oncology
• Metabolic pathways
• Cancer cell biology

Background:

• Exploiting metabolic vulnerabilities in cancer cells is a growing therapeutic strategy.
• Kinase inhibitors (KIs) and biguanides show potential for synergistic anti-cancer effects.

Purpose of the Study:

• To investigate the mechanisms underlying the synergistic efficacy of kinase inhibitor and biguanide combinations in cancer cells.
• To identify key metabolic pathways and regulatory axes that determine sensitivity to these combined therapies.

Main Methods:

• Assessing the synergistic effects of kinase inhibitors and biguanides on various cancer cell lines.
• Analyzing the role of non-essential amino acid (NEAA) synthesis and glutamine metabolism.
• Investigating the mTORC1/4E-BP signaling pathway and its impact on mRNA translation.
• Evaluating the influence of hypoxia-inducible factor 1-alpha (HIF-1α) in VHL-deficient renal cancer cells.

Main Results:

• KI/biguanide combinations demonstrated synergistic and selective targeting of diverse cancer cells.
• Non-essential amino acid synthesis (aspartate, asparagine, serine) and glutamine metabolism are critical for combination efficacy.
• The mTORC1/4E-BP axis regulates NEAA synthesis via mRNA translation; its ablation reduces sensitivity.
• HIF-1α-dependent alterations in glutamine metabolism affect combination efficacy in renal cancer cells.

Conclusions:

• Cancer cells exhibit metabolic plasticity, employing adaptive mechanisms to survive therapies targeting their metabolism.
• Understanding these adaptive pathways is crucial for optimizing combination therapies involving kinase inhibitors and biguanides.
• Targeting specific metabolic vulnerabilities, such as NEAA and glutamine metabolism, can enhance anti-cancer treatment strategies.